 | Up a level |
Journal Article
Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407
Vehreschild, Maria J. G. T., Meissner, Arne M. K., Cornely, Oliver Andreas, Maschmeyer, Georg, Neumann, Silke, von Lilienfeld-Toal, Marie, Karthaus, Meinholf, Wattad, Mohammed, Staib, Peter, Hellmich, Martin 
ORCID: 0000-0001-5174-928X, Christ, Hildegard ORCID: 0000-0003-3235-2994 and Vehreschild, Joerg Janne
(2011).
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.
Haematol-Hematol. J., 96 (12).
S. 1855 - 1861.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078